3D Medicines Says Envafoimab Granted Orphan Drug Designation

About this update from 3d Medicines, Inc.

3D Medicines Inc HKEX:1244:ENVAFOIMAB GRANTED ORPHAN DRUG DESIGNATIONDESIGNATION FOR TREATMENT OF GASTRIC CANCER AND - GASTRO-ESOPHAGEAL JUNCTION CANCER INDICATIONS BY CHINA NMPA

View stock analysis, news, and events for 3d Medicines, Inc.